Make an Inquiry
Accelerating Constipation Drug Development

Constipation remains a significant and often under-addressed therapeutic challenge, impacting patient quality of life and presenting complex hurdles in drug development. Ace Therapeutics is dedicated exclusively to advancing preclinical drug development for Constipation, serving as a specialized partner for pharmaceutical innovators seeking targeted solutions in this field. Ace Therapeutics offers a comprehensive suite of preclinical services, encompassing target validation, lead optimization, pharmacology, safety pharmacology, and IND-enabling studies. Our approach integrates deep scientific expertise with state-of-the-art in vitro and in vivo platforms specifically tailored to the pathophysiology of Constipation. Rigorous adherence to global regulatory standards ensures that every study meets the highest benchmarks for data integrity and translational value. With a proven track record in gastrointestinal drug development, Ace Therapeutics combines scientific rigor, advanced technology, and regulatory insight to de-risk and accelerate Constipation therapeutic programs. Our commitment is to enable partners to achieve meaningful breakthroughs—bringing novel, effective treatments for Constipation closer to patients in need.

What is ConstipationTargets for ConstipationDrug Discovery and Development ServicesWhy Choose Us

What is Constipation

Constipation is a common gastrointestinal disorder characterized by infrequent, difficult, or incomplete defecation, typically defined as fewer than three bowel movements per week. Its etiology is multifactorial, encompassing primary (idiopathic) forms—such as normal transit, slow transit, and defecatory disorders—as well as secondary causes linked to medications, metabolic or endocrine disturbances, neurologic conditions, or structural abnormalities. The underlying pathophysiology involves alterations in colonic motility, pelvic floor dysfunction, impaired rectal sensation, and changes in gut microbiota. Specific forms include opioid-induced constipation, related to opioid therapy, and irritable bowel syndrome with constipation (IBS-C), which features altered gut-brain signaling and visceral hypersensitivity. Clinically, constipation presents with symptoms such as hard or lumpy stools, excessive straining, a sensation of incomplete evacuation, and reduced stool frequency, often leading to discomfort and complications like hemorrhoids or anal fissures. Diagnosis is primarily clinical, guided by Rome IV criteria, and may be supplemented by laboratory tests, endoscopy, or specialized motility studies to exclude secondary causes or alarm features. Management includes dietary and lifestyle modifications, addressing underlying conditions, and pharmacologic therapies such as osmotic and stimulant laxatives, guanylate cyclase-C agonists, serotonin 5-HT4 agonists, chloride channel activators, and peripherally acting opioid antagonists for opioid-induced cases.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-439087-18-0-elobixibat-prop-inn-usan elobixibat (Prop INN; USAN) 439087-18-0 C36 H45 N3 O7 S2 695.888
img-467426-54-6-guanilibplecanatide-prop-inn-usan guanilib; plecanatide (Prop INN; USAN) 467426-54-6 C65 H104 N18 O26 S4 1681.886
img-851199-60-5-linaclotide-acetate-prop-innm-usan linaclotide acetate (Prop INNM; USAN) 851199-60-5 C59 H79 N15 O21 S6 . C2 H4 O2 1586.788
img-179474-85-2-prucalopride-succinate-prop-innm-usan prucalopride succinate (Prop INNM; USAN) 179474-85-2 C18 H26 Cl N3 O3 . C4 H6 O4 485.958
img-73232-52-7-methylnaltrexone-bromide-prop-inn-usan methylnaltrexone bromide (Prop INN; USAN) 73232-52-7 C21 H26 N O4 . Br 436.339
polyethylene glycol 3350
img-333963-40-9-lubiprostone-rec-inn-usan lubiprostone (Rec INN; USAN) 333963-40-9 C20 H32 F2 O5 390.462
25322-68-3
img-585-86-4-lactitol-rec-inn-ban lactitol (Rec INN; BAN) 585-86-4 C12 H24 O11 344.312
img-10040-45-6-sodium-picosulfate sodium picosulfate 10040-45-6 C18 H13 N O8 S2 . 2 Na 481.407

Learn More

Targets for Constipation

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
5-hydroxytryptamine receptor 4 HTR4
chloride voltage-gated channel 2 CLCN2
mucin 5AC, oligomeric mucus/gel-forming MUC5AC
solute carrier family 10 member 2 SLC10A2
protein tyrosine phosphatase non-receptor type 1 PTPN1
opioid receptor mu 1 OPRM1
guanylate cyclase 2C GUCY2C
cholecystokinin A receptor CCKAR
5-Hydroxytryptamine Receptor 3 (5-HT3 receptor) (nonspecified subtype)
growth hormone secretagogue receptor GHSR

Constipation is driven by disruptions in both neurotransmitter signaling and epithelial ion transport, with several molecular targets playing pivotal roles in disease pathogenesis. Key neurotransmitter-related targets include 5-hydroxytryptamine receptor 4 (HTR4), acetylcholinesterase (ACHE), cholinergic receptor muscarinic 1 (CHRM1), cholecystokinin A receptor (CCKAR), and opioid receptors (OPRM1, OPRK1). These proteins regulate excitatory and inhibitory pathways in the enteric nervous system, influencing peristalsis, colonic transit, and visceral sensation. In parallel, ion transport and fluid secretion are governed by targets such as chloride voltage-gated channel 2 (CLCN2), guanylate cyclase 2C (GUCY2C), and solute carrier family 10 member 2 (SLC10A2), which modulate chloride and water secretion as well as bile acid reabsorption, directly affecting stool consistency and transit time. Therapeutically, these targets offer robust avenues for intervention. Selective HTR4 agonists (e.g., prucalopride) and peripherally restricted opioid antagonists (e.g., methylnaltrexone) are already approved for chronic and opioid-induced constipation, respectively, demonstrating clinical efficacy. Agents activating CLCN2 (lubiprostone) or GUCY2C (linaclotide, plecanatide) enhance epithelial secretion and are established treatments for chronic constipation and IBS-C. Inhibitors of SLC10A2, such as elobixibat, are emerging therapies targeting bile acid pathways. Ongoing research into CCKAR, CHRM1, and OPRK1 continues to expand the therapeutic landscape, supporting precision medicine approaches for tailored constipation management.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates constipation drug discovery by providing robust, sensitive assays for key gastrointestinal targets. We offer comprehensive biochemical, cell-based, radioligand binding, and functional assays to evaluate compound efficacy, potency, and mechanism of action. Our platforms assess receptors, ion channels, and enzymes implicated in motility, secretion, and neurotransmission. Quantitative parameters such as EC-50, IC-50, Ki, and pEC-50 enable precise comparison and optimization of candidates. Leveraging advanced technologies, we deliver data-driven insights to guide preclinical development, ensuring efficient selection of promising therapeutics for constipation with scientific rigor and industry-leading expertise.

5-Hydroxytryptamine Receptor 4 Acetylcholinesterase (Yt Blood Group)
Chloride Voltage-Gated Channel 2 Cholecystokinin A Receptor
Cholinergic Receptor Muscarinic 1 Diacylglycerol O-Acyltransferase 1
Growth Hormone Secretagogue Receptor Guanylate Cyclase 2C
Mucin 5Ac, Oligomeric Mucus/Gel-Forming Opioid Receptor Kappa 1
Opioid Receptor Mu 1 Opioid Related Nociceptin Receptor 1
Relaxin Family Peptide/Insl5 Receptor 4 Solute Carrier Family 10 Member 2

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the field of Constipation therapeutics through our specialized expertise in research and drug development. Our professional teams consist of experienced scientists and industry experts who are deeply committed to delivering innovative solutions for Constipation. Leveraging advanced technology platforms, we ensure that every stage of preclinical drug development is conducted with precision and efficiency. Ace Therapeutics has established a strong track record of reliability, consistently providing high-quality preclinical development services that meet the unique needs of our clients. We adhere to the highest quality standards and maintain strict regulatory compliance, ensuring that all our processes and outcomes are robust and dependable. Our unwavering commitment to scientific excellence and patient well-being drives us to continuously push the boundaries of Constipation drug development. By choosing Ace Therapeutics, you partner with a team that not only understands the complexities of Constipation therapeutics but is also dedicated to bringing safe and effective treatments closer to those in need.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for constipation?

A: One of the primary challenges in preclinical research for constipation is the selection and validation of appropriate animal models that accurately mimic human gastrointestinal physiology and the pathophysiology of constipation. Additionally, assessing drug efficacy and safety requires robust endpoints, such as stool frequency, consistency, and transit time, which can be difficult to measure consistently across models. Our company addresses these challenges by utilizing a range of validated rodent and non-rodent models, employing advanced imaging and biomarker analyses, and continuously updating our protocols to reflect the latest scientific insights.

Q: What regulatory considerations are important in the preclinical development of constipation drugs?

A: Regulatory agencies such as the FDA and EMA require comprehensive safety and efficacy data in preclinical studies before approving progression to clinical trials. For constipation drugs, this includes detailed pharmacodynamic and pharmacokinetic profiling, toxicology assessments, and evaluation of off-target effects, especially given the potential for systemic absorption of gastrointestinal agents. Our team has extensive experience in designing preclinical programs that align with global regulatory guidelines, ensuring that all necessary data packages are complete and compliant to facilitate a smooth transition to clinical development.

Q: What are the key technical aspects to consider during preclinical research for constipation treatments?

A: Technical considerations include the choice of in vitro and in vivo models, the use of advanced imaging techniques to monitor gastrointestinal motility, and the measurement of relevant biomarkers. It is also essential to simulate human-like conditions, such as diet-induced or drug-induced constipation, to better predict clinical outcomes. Our company leverages state-of-the-art laboratories and technologies, including telemetry, high-throughput screening, and molecular assays, to provide detailed mechanistic insights and support robust data generation.

Q: How do timeline and cost considerations impact preclinical constipation drug development?

A: Preclinical development timelines and costs can vary significantly depending on the complexity of the compound and the required studies. Constipation drug development may require additional model validation and extended safety studies, potentially increasing both duration and cost. However, with efficient project management and integrated service offerings, our company streamlines workflows and leverages automation to reduce turnaround times and optimize budgets, providing clients with transparent timelines and cost estimates at every stage.

Q: What are the critical success factors for preclinical drug development targeting constipation?

A: Success in preclinical constipation drug development hinges on several factors: selecting predictive and translational animal models, generating high-quality and reproducible data, adhering to regulatory requirements, and maintaining clear communication with stakeholders. Our expertise in gastrointestinal pharmacology, combined with a commitment to scientific rigor and regulatory compliance, enables us to deliver reliable results and accelerate the path to clinical trials for our clients.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.